Along with the nonenzymatic conversion of Metriphonate, a long-acting irreversible organophosphate AChE inhibitor, to the active ingredient Dichlorvos; (Figure 2), clinical trials were started to treat AD patients because of its capacity to improve cholinergic neurotransmission in the CNS. The gene discussed is ACHE; the disease is Alzheimer disease.